Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Idenix, Novartis deal

IDIX and NVS amended a 2003 agreement, transferring responsibility for development, manufacturing and commercializing HBV drug Tyzeka telbivudine (Sebivo-EU) from IDIX to NVS, which owns

Read the full 251 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE